X
[{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Johnson & Johnson Discussions to License its COVID-19 Vaccine to Aspen Reach Advanced Stage","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SOUTH AFRICA","productType":"Vaccine","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Aspen Pharmacare Holdings"},{"orgOrder":0,"company":"The Biovac Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfizer,BioNTech Collaborate with Biovac to Manufacture, Distribute COVID-19 Vaccine Doses within Africa","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SOUTH AFRICA","productType":"Vaccine","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"The Biovac Institute"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
The license under discussion would enable Aspen, using COVID-19 vaccine JNJ-78436735, drug substance supplied by Johnson & Johnson, to produce Aspen-branded finished vaccine for sale to public sector markets in Africa.
Lead Product(s):
Ad26.COV2.S
Therapeutic Area: Infections and Infectious Diseases
Product Name: JNJ-78436735
Highest Development Status: Approved
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Johnson & Johnson
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
November 30, 2021
Details:
Biovac will perform manufacturing and distribution activities within Pfizer’s and BioNTech’s Covid Vaccine, BNT162b2's global supply chain and manufacturing network, which will now span three continents and include more than 20 manufacturing facilities.
Lead Product(s):
Tozinameran
Therapeutic Area: Infections and Infectious Diseases
Product Name: BNT162b2
Highest Development Status: Approved
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Pfizer Inc
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
July 21, 2021